Amneal Non Current Liabilities Total from 2010 to 2025
| AMRX Stock | USD 8.28 0.01 0.12% |
Non Current Liabilities Total | First Reported 2016-12-31 | Previous Quarter 2.4 B | Current Value 1.3 B | Quarterly Volatility 589.2 M |
Check Amneal Pharmaceuticals, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amneal Pharmaceuticals,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 164.4 M, Interest Expense of 134.8 M or Selling General Administrative of 303.3 M, as well as many indicators such as Price To Sales Ratio of 0.83, Dividend Yield of 0.096 or Days Sales Outstanding of 132. Amneal financial statements analysis is a perfect complement when working with Amneal Pharmaceuticals, Valuation or Volatility modules.
Amneal | Non Current Liabilities Total |
Latest Amneal Pharmaceuticals,'s Non Current Liabilities Total Growth Pattern
Below is the plot of the Non Current Liabilities Total of Amneal Pharmaceuticals, Class over the last few years. It is Amneal Pharmaceuticals,'s Non Current Liabilities Total historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Amneal Pharmaceuticals,'s overall financial position and show how it may be relating to other accounts over time.
| Non Current Liabilities Total | 10 Years Trend |
|
Non Current Liabilities Total |
| Timeline |
Amneal Non Current Liabilities Total Regression Statistics
| Arithmetic Mean | 1,810,634,711 | |
| Geometric Mean | 1,604,989,417 | |
| Coefficient Of Variation | 49.35 | |
| Mean Deviation | 839,923,925 | |
| Median | 1,420,588,000 | |
| Standard Deviation | 893,542,569 | |
| Sample Variance | 798418.3T | |
| Range | 2B | |
| R-Value | 0.72 | |
| Mean Square Error | 417458.3T | |
| R-Squared | 0.51 | |
| Significance | 0 | |
| Slope | 134,294,007 | |
| Total Sum of Squares | 11976274.9T |
Amneal Non Current Liabilities Total History
About Amneal Pharmaceuticals, Financial Statements
Amneal Pharmaceuticals, investors use historical fundamental indicators, such as Amneal Pharmaceuticals,'s Non Current Liabilities Total, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Amneal Pharmaceuticals,. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Non Current Liabilities Total | 1.3 B | 2.4 B |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Amneal Stock Analysis
When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.